CC-92480
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $1.1M | 22 | 9 |
| 2018 | $602,667 | 8 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.7M | 15 | 99.9% |
| Travel and Lodging | $2,040 | 7 | 0.1% |
| Food and Beverage | $311.62 | 8 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1, Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Dosing of CC-92480 and to Explore the Effect of Food on the Bioavailability of CC-92480 in Healthy Subjects (CC-92480-CO-001) | Celgene Corporation | $710,325 | 0 |
| A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (CC-92480-MM-001) | Celgene Corporation | $360,445 | 0 |
| CC-92480-CP-001 - Phase 1 Safety/Tol/PK/PD/Food/BA (CC-92480-CP-001) (BMS Study Number: CA057-P02) | Celgene Corporation | $304,168 | 0 |
| CC-92480-MM-001 - A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | Celgene Corporation | $298,463 | 0 |
| Phase 1 Safety/Tol/PK/PD/Food/BA (CC-92480-CP-001) (BMS Study Number: CA057-P02) (CC-92480-CP-001) | Celgene Corporation | $66.00 | 0 |
Top Doctors Receiving Payments for CC-92480
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Duarte, CA | $1.7M | 15 |
| , MD | Hematology & Oncology | Boston, MA | $879.11 | 3 |
| , M.D | Hematology & Oncology | Nashville, TN | $497.34 | 3 |
| , M.D | Hematology | Cleveland, OH | $417.92 | 3 |
| , M.D | Hematology & Oncology | Denver, CO | $335.49 | 1 |
| , MD | Hematology & Oncology | Tampa, FL | $53.65 | 1 |
| , MD | Hospitalist | Saint Louis, MO | $53.65 | 1 |
| , MD, PHD | Hematology & Oncology | Tampa, FL | $53.65 | 1 |
| , M.D | Medical Oncology | Tampa, FL | $53.65 | 1 |
| , MD | Hematology & Oncology | Atlanta, GA | $7.57 | 1 |
Manufacturing Companies
- Celgene Corporation $1.7M
Product Information
- Type Drug
- Total Payments $1.7M
- Total Doctors 9
- Transactions 30
About CC-92480
CC-92480 is a drug associated with $1.7M in payments to 9 healthcare providers, recorded across 30 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2018 to 2019. In 2019, $1.1M was paid across 22 transactions to 9 doctors.
The most common payment nature for CC-92480 is "Unspecified" ($1.7M, 99.9% of total).
CC-92480 is associated with 5 research studies, including "A Phase 1, Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Dosing of CC-92480 and to Explore the Effect of Food on the Bioavailability of CC-92480 in Healthy Subjects (CC-92480-CO-001)" ($710,325).